Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

6.930 +2.120 (+44.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,621,494
Open 7.220
Bid (Size) 6.710 (1)
Ask (Size) 6.770 (1)
Prev. Close 4.810
Today's Range 6.060 - 7.400
52wk Range 3.500 - 12.40
Shares Outstanding 49,383,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here are the top movers in Monday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga

Performance

YTD
-2.5%
-2.5%
1 Month
+51.3%
+51.3%
3 Month
+43.8%
+43.8%
6 Month
+3.0%
+3.0%
1 Year
+23.3%
+23.3%

More News

Read More
Which stocks are moving on Monday?
Via Chartmill
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Via Benzinga
Monday's session: gap up and gap down stocks
Via Chartmill
Monday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa (GLUE) Q2 Revenue Jumps 394%
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected
Via Chartmill
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Via Benzinga
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
Via Benzinga
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 6.930
When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 09/15/25 04:00 PM ET
What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 342.23M
How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
Monte Rosa Therapeutics, Inc. - Common Stock has 342M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.